Salix Pharmaceuticals (Morrisville) has acquired the rights to metoclopramide-Zydis, a short-term therapy for adults with symptomatic documented gastroesophageal reflux from Wilmington Pharmaceuticals.
Wilmington Pharmaceuticals (Wilmington) plans to file a New Drug Application for their Zydis formulation of metoclopramide with the U.S. Food and Drug Administration during the fourth quarter of 2007. The product has patent protection until 2022, and additional patent protection pending that, if issued, will provide patent protection until 2025.
Salix is required to make a small up-front payment to Wilmington, a regulatory milestone payment to Wilmington upon NDA approval and to pay royalties to Wilmington on net sales.
"Salix is expanding its product portfolio with the acquisition of a fast-dissolving formulation of metoclopramide," said Carolyn Logan, Salix president and Chief Executive Officer. "Market research indicates a high level of demand for a patient-friendly formulation of this widely-prescribed agent."
Read the complete news release